Efficacy and Feasibility of Sorafenib as a Maintenance Agent after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: an update

Patients diagnosed with acute myeloid leukemia (AML) with Fms-like tyrosine kinase 3 (FLT3) mutations have a very poor prognosis[1]. Use of allogeneic hematopoietic stem cell transplantation is now a standard practice in this setting of patients, but disease relapse may occur, with difficulties to obtain a complete remission despite salvage treatments[2]. More recently, the incorporation of FLT3-inhibitors in the treatment of these patients has shown promising results[3][4].

Source: Clinical Lymphoma, Myeloma and Leukemia - April 16, 2019 Category: Hematology Authors: Giorgia Battipaglia, Radwan Massoud, Syed Osman Ahmed, Ollivier Legrand, Jean El Cheikh, Riad Youniss, Mahmoud Aljurf, Mohamad Mohty, Ali Bazarbachi Tags: Original Study Source Type: research